|OUR PROGRAMS||OUR SCIENCE||RESOURCE LINKS||NEWS||ABOUT US|
Acumen Pharmaceuticals Immunotherapy & ACU-193
Immunotherapy and ACU-193
Antibodies with selective affinity against soluble Aß oligomers / ADDLs represent the core technology of Acumen. ACU-193, the lead antibody within the Acumen anti-ADDL antibody program, is a fully humanized, IgG2 monoclonal antibody, capable of selective binding ADDLs and potent blocking of their deleterious actions. Several backup product candidates have been generated in the program.
ACU-193 has been derived from the murine monoclonal anti-ADDL antibody 3B3, originally identified by Acumen scientists. ACU-193 emerged from an eight year partnership with Merck & Co., Inc. directed at anti-ADDL immunotherapy. The partnership was dissolved by mutual agreement in 2011, when all rights and materials related to ACU-193 and the anti-ADDL program reverted to Acumen.
|Home | Contact Us | Our Programs | Our Science | News | Site Map|
|Copyright © 2014 Acumen Pharmaceuticals, Inc.|